Leerink Partners Downgrades Caribou Biosciences to Market Perform, Lowers Price Target to $1
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsDowngradesPrice Target
Leerink Partners analyst Daina Graybosch downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Market Perform and lowers the price target from $4 to $1.
Leerink Partners analyst Daina Graybosch downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Market Perform and lowers the price target from $4 to $1.